Renovaro (RENB) Competitors $0.28 0.00 (-0.47%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.29 +0.01 (+3.96%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. IMMP, ACB, SLRN, CGC, TVGN, BTMD, INBX, DSGN, ESPR, and NBTXShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Prima BioMed (IMMP), Aurora Cannabis (ACB), Acelyrin (SLRN), Canopy Growth (CGC), Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors Prima BioMed Aurora Cannabis Acelyrin Canopy Growth Semper Paratus Acquisition biote Inhibrx Biosciences Design Therapeutics Esperion Therapeutics Nanobiotix Prima BioMed (NASDAQ:IMMP) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media prefer IMMP or RENB? In the previous week, Renovaro had 4 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Renovaro and 0 mentions for Prima BioMed. Renovaro's average media sentiment score of 0.42 beat Prima BioMed's score of 0.00 indicating that Renovaro is being referred to more favorably in the news media. Company Overall Sentiment Prima BioMed Neutral Renovaro Neutral Which has more volatility & risk, IMMP or RENB? Prima BioMed has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Do analysts recommend IMMP or RENB? Prima BioMed presently has a consensus target price of $7.00, suggesting a potential upside of 309.36%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities analysts plainly believe Prima BioMed is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in IMMP or RENB? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, IMMP or RENB? Prima BioMed has higher revenue and earnings than Renovaro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M48.59-$28.01MN/AN/ARenovaroN/AN/A-$88.43M-$0.77-0.36 Is IMMP or RENB more profitable? Prima BioMed's return on equity of 0.00% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Renovaro N/A -60.38%-47.04% SummaryPrima BioMed beats Renovaro on 8 of the 12 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.85M$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.3621.7127.7020.25Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book0.317.538.035.65Net Income-$88.43M-$55.14M$3.18B$249.15M7 Day Performance-3.77%4.22%2.88%2.91%1 Month Performance-10.00%0.91%1.67%4.11%1 Year Performance-82.63%5.40%34.39%20.98% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.1238 of 5 stars$0.28-0.5%N/A-82.6%$47.85MN/A-0.3620Gap UpIMMPPrima BioMed0.97 of 5 stars$1.52-5.0%$7.00+360.5%-11.9%$233.66M$5.14M0.002,021Positive NewsACBAurora Cannabis0.1945 of 5 stars$3.91-4.2%N/A-5.1%$229.35M$246.72M35.551,073SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth2.8399 of 5 stars$1.19-4.0%$2.00+68.1%-79.6%$227.99M$225.65M-0.293,150Positive NewsTVGNSemper Paratus Acquisition3.9852 of 5 stars$1.16-3.3%$7.10+512.1%+77.9%$220.67MN/A0.003Positive NewsBTMDbiote3.0867 of 5 stars$4.01+1.3%$8.00+99.5%-43.0%$216.65M$197.19M6.57194Positive NewsINBXInhibrx Biosciences0.9886 of 5 stars$14.56-2.5%N/A+26.3%$216.12M$200K0.12166DSGNDesign Therapeutics0.3635 of 5 stars$3.90+4.3%$4.00+2.6%+10.2%$212.32MN/A-3.9440Positive NewsESPREsperion Therapeutics4.2201 of 5 stars$1.04-2.8%$7.00+573.1%-52.2%$212.07M$332.31M-1.30200NBTXNanobiotix1.6806 of 5 stars$4.45-0.5%$8.00+79.8%-8.2%$210.68M-$11.61M0.00100Positive NewsGap Up Related Companies and Tools Related Companies Prima BioMed Alternatives Aurora Cannabis Alternatives Acelyrin Alternatives Canopy Growth Alternatives Semper Paratus Acquisition Alternatives biote Alternatives Inhibrx Biosciences Alternatives Design Therapeutics Alternatives Esperion Therapeutics Alternatives Nanobiotix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
